---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001076"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:32:09.762729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aclaris ATI-052 Phase 1a shows favorable safety, 26-day half-life, near-complete target inhibition at low doses

## Summary
- ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.
- PK profile shows at least 26-day effective half-life with dose-proportional Cmax and AUC.
- At 30 mg, robust concentration-dependent inhibition of IL-4 and TSLP stimulated CCL17/TARC.
- Data supports potential for up to every-3-month dosing; Phase 1b in AD and asthma to start Q1 2026.
- Phase 2b in atopic dermatitis planned for H2 2026; top-line data from Phase 1b expected H2 2026.

## SEC filing metadata
- accession: 0001104659-26-001076
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/0001104659-26-001076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001076
- JSON: https://secwatch.observer/filing/0001104659-26-001076.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.